


PHARMACEUTICAL 2018

DYNAVAX TECHNOLOGIES CORP Rank 151 of 349 **DYN/VAX**







PHARMACEUTICAL 2018

DYNAVAX TECHNOLOGIES CORP Rank 151 of 349

The relative strengths and weaknesses of DYNAVAX TECHNOLOGIES CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of DYNAVAX TECHNOLOGIES CORP compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 256% points. The greatest weakness of DYNAVAX TECHNOLOGIES CORP is the variable Net Income, reducing the Economic Capital Ratio by 104% points.

The company's Economic Capital Ratio, given in the ranking table, is -135%, being 142% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	198,023
Cost of Goods Sold	0
Intangible Assets	2,244
Liabilities, Current	18,593
Liabilities, Non-Current	643
Other Assets	1,899
Other Compr. Net Income	2,743
Other Expenses	3,977
Other Liabilities	0
Other Net Income	851
Property and Equipment	16,619
Research and Development	64,988
Revenues	327
Selling, General and Administrative Expense	27,367

Output Variable	Value in 1000 USD
Assets	218,785
Liabilities	19,236
Expenses	96,332
Stockholders Equity	199,549
Net Income	-95,154
Comprehensive Net Income	-93,782
Economic Capital Ratio	-135%

DYNAVAX

